Tumor hypoxia, DNA repair and prostate cancer regression: New targets and new therapies

Future Oncology

Volumn 3, Issue 3, 2007, Pages 329-341

  Chan, Norman ^a   Milosevic, Michael ^a   Bristow, Robert G ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Androgen deprivation; Biomarkers cancer therapy; Carcinogenesis; DNA repair homologous recombination; Hypoxia; Prostate cancer; Rad51; Radiotherapy

Indexed keywords

2 NITROIMIDAZOLE DERIVATIVE; BICALUTAMIDE; CARBONATE DEHYDRATASE; CHECKPOINT KINASE 2; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; OXYGEN; PIMONIDAZOLE; VASCULOTROPIN;

CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; CASTRATION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DNA REPAIR; DNA STRAND BREAKAGE; EXTERNAL BEAM RADIOTHERAPY; GENE EXPRESSION; HUMAN; HYPOXIA; IMMUNOHISTOCHEMISTRY; NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGEN DIFFUSION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; REVIEW; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANOXIA; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DNA REPAIR; DRUG DESIGN; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; PROSTATIC NEOPLASMS;

EID: 34347389461     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.3.3.329     Document Type: Review

References (67)

1. Nichol AM, Warde P, Bristow RG: Optimal treatment of intermediate-risk prostate carcinoma with radiotherapy-clinical and translational issues. Cancer 104(5), 891-905 (2005).
2. Kupelian PA, Potters L, Khuntia D et al.: Radical prostatectomy, external beam radiotherapy <72 Gy. external beam radiotherapy ≥72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 58(1), 25-33 (2004).
3. Ljungkvist AS, Bussink J, Kaanders JH, Wiedenmann NE, Vlasman R, van der Kogel AJ: Dynamics of hypoxia, proliferation and apoptosis after irradiation in a murine tumor model. Radiat. Res. 165 (3), 326-336 (2006).
4. Brown JM, Wilson WR: Exploiting tumour hypoxia in cancer treatment. Nat. Rev. Cancer 4(6), 437-447 (2004).
5. Harris AL: Hypoxia - a key regulatory factor in tumour growth. Nat. Rev. Cancer 2(1), 38-47 (2002).
6. Bristow R, Hill R: Molecular and cellular radiobiology. In: The Basic Science of Oncology. Tannock I et al. (Eds). McGraw-Hill Ltd, New York, USA 261-288 (2005).
7. Primeau AJ, Rendon A, Hedley D, Lilge L, Tannock IF: The distribution of the anticancer drug doxorubicin in relation to blood vessels in solid tumors. Clin. Cancer Res. 11(24 Pt 1), 8782-8788 (2005).
8. Cairns RA, Hill RP: Acute hypoxia enhances spontaneous lymph node metastasis in an orthoropic murine model of human cervical carcinoma. Cancer Res. 64(6), 2054-2061 (2004).
9. Martinive P, Deftesne F, Bouzin C et al.: Preconditioning of the tumor vasculature and tumor cells by intermittent hypoxia: implications for anticancer therapies. Cancer Res. 66(24), 11736-11744 (2006).
10. Koritzinsky M, Magagnin MG, van den Beucken T et al.: Gene expression during acute and prolonged hypoyia is regulated by distinct mechanisms of translational control. EMBO J. 25(5),1114-1125 (2006).
11. Subarsky P, Hill RP: The hypoxic tumour microenvironment and metastatic progression. Clin. Exp. Metastasis 20(3), 237-250 (2003).
12. Milosevic M, Fyles A, Hedley D, Hill R: The human tumor microenvironment: invasive (needle) measurement of oxygen and interstitial fluid pressure. Semin. Radiat. Oncol. 14(3), 249-258 (2004).
13. Vaupel P, Kelleher DK, Hockel M: Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin. Oncol. 28(2 Suppl. 8), 29-35 (2001).
14. Brizel DM, Scully SP Harrelson JM et al.: Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 56(5), 941-943 (1996).
15. Parker C, Milosevic M, Toi A et al.: Polarographic electrode study of tumor clinically localized prostate cancer. Int. J. Rad. Onc. Biol. Phys. 58(3), 750-757 (2004).
16. Movsas B, Chapman JD, Hanlon AL et al.: Hypoxic prostate/muscle pO2 ratio predicts for biochemical failure in patients with prostate cancer: preliminary findings. Urology 60(4), 634-639 (2002).
17. Milosevic M: Androgen withdrawal in patients reduces prostate cancer hypoxia: implications fbr disease progression and radiation response. Cancer Res. (2007) (In Press).
18. Bindra RS, Glazer PM: Repression of RAD51 gene expression by E2F4/p130 complexes in hypoxia. Oncogene 26(14), 2048-2057 (2007).
19. Meng AX, Jalali F, Cuddihy A et al.: Hypoxia down-regulates DNA double strand break repair gene expression in prostate cancer cells. Radiother. Oncol. 76(2), 168-176 (2005).
20. 2-dependent degradation domain via die ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. USA 95(14), 7987-7992 (1998).
21. 2 homeostasis by hypoxia-inducible factor 1. Annu. Rev. Cell Dev. Biol. 15, 551-578 (1999).
22. Vaupel P: Tumor microenvironmental physiology and its implications for radiation oncology. Semin. Radiat. Oncol. 14(3), 198-206 (2004).
23. Semenza GL: HIF-1 and human disease: one highly involved factor. Genes Dev. 14(16), 1983-1991 (2000).
24. Salceda S, Caro J: Hypoxia-inducible factor 1α (HIF-1α) protein is rapidly degraded by the ubiquitin-prowasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J. Biol. Chem. 272(36), 22642-22647 (1997).
25. Cockman ME, Masson N, Mole DR et al.: Hypoxia inducible factor-α binding and ubiquitylation by die von Hippel-Lindau tumor suppressor protein. J. Biol. Chem. 275(33), 25733-25741 (2000).
26. Maxwell PH, Wiesener MS, Chang GW et al.: The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399(6733), 271-275 (1999).
27. Meng AX, Jalali F, Cuddihy A et al.: Hypoxia down-fegulates DNA double strand break repair gene expression in prostate cancer cells. Radiother. Oncol. 76(2), 168-176 (2005).
28. Koshiji M, Kageyama Y, Pete EA, Horikawa I, Barrett JC, Huang LE: HIF-1α induces cell cycle arrest by functionally counteracting Myc. EMBO J. 23, 1949-1956 (2004).
29. Koritzinsky M, Seigneuric R, Magagnin MG, van den Beucken T, Lambin P, Wouters BG: The hypoxic proteome is influenced by gene-specific changes in mRNA translation. Radiother. Oncol. 76(2), 177-186 (2005).
30. Wouters BG, van den Beucken T, Magagain MG, Koritzinsky M, Fels D, Kournenis C: Control of the hypoxic response through regulation of mRNA translation. Semin. Cell Dev. Biol. 16(4-5), 487-501 (2005).
31. Ramankulov A, Lein M, Kristiansen G, Loening SA, Jung K: Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer. Prostate 67(3), 330-340 (2007).
32. Woodward WA, Vaclisberger P, Burd R, Dicker AP: Effects of androgen suppression and radiation on prostate cancer suggest a role for angiogenesis blockade. Prostate Cancer Prostatic. Dis. 8(2), 127-132 (2005).
33. Jain RY, Duda DG, Clark JW, Loeffler JS: Lessons from Phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol. 3(1), 24-40 (2006).
34. Charlesworth PJ, Harris AL: Mechanisms of disease: angiogenesis in urologic malignancies. Nat. Clin. Pract. Urol. 3(3), 157-169 (2006).
35. Green MM, Hiley CT, Shanks JH et al.: Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic fbr radiotherapy outcome. Int. J. Radiat. Oncol. Biol. Phys. 670), 84-90 (2007).
36. Moeller BJ, Cao Y, Li CY, Dewhirst MW: Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 5(5), 429-441 (2004).
37. Dewhirst MW: Intermittent hypoxia furthers the rationale for hypoxia-inducible factor-1 targeting. Cancer Res. 67(3), 854-855 (2007).
38. Carnell DM, Smith RE, Daley FM, Saunders MI, Bentzen SM, Hoskin PJ: An immunohistochemical assessment of hypoxia in prostate carcinoma using pimonidazole: implications for radioresistance. Int. J. Radiat. Oncol. Biol. Phys. 65(1), 91-99 (2006).
39. Tatum JL, Kelloff GJ, Gillies RJ et al.: Hypoxia: importance in tumor biology, noninvasive measurement by imaging and value of its measurement in the management of cancer therapy. Int. J. Radiat. Biol. 82(10), 699-757 (2006).
40. Henderson E, Milosevic MF, Haider MA, Yeung IW: Functional CT imaging of prostate cancer. Phys. Med. Biol. 48(18), 3085-3100 (2003).
41. Buckley DL, Robercs C, Parker GJ, Logue JP, Hutchinson CE: Prostate cancer: evaluation of vascular characteristics with dynamic contrast-enhanced T1-weighted MR imaging - initial experience. Radiology 233(3), 709-715 (2004).
42. Bourke VA, Zhao D, Gilio J et al.: Correlation of radiation response with tumor oxygenation in the Dunning prostate R3327-AT1 tumor. Int. J. Radiat. Oncol. Biol. Phys. 67(4), 1179-1186 (2007).
43. Rasey JS, Koh WJ, Evans ML et al.: Quantifying regional hypoxia in human tumors with positron emission tomography of (18F)-fluoromisonidazole: a pretherapy study of 37 patients. Int. J. Radiat. Oncol. Biol. Phys. 36(2), 417-428 (1996).
44. Yapp DT, Woo J, Kartono A, Sy J, Oliver T, Skov KA et al.: Non-invasive evaluation of tumour hypoxia in the Shionogi tumour model for prostate cancer with F-EF5 and positron emission tomography. BJU Int. 99(5), 1154-1160 (2007).
45. Graeber TG, Osmanian C, Jacks T et al.: Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379(6560), 88-91 (1996).
46. Coffey RN, Morrissey C, Taylor CT, Fitzpatrick JM, Watson RA: Resistance to caspase-dependent, hypoxia-induced apoptosis is not hypoxia-inducible factor-1α mediated in prostate carcinoma cells. Cancer 103(7), 1363-1374 (2005).
47. Gibson SL, Bindra RS, Glazer PM: Hypoxia-induced phosphorylation of Chk2 in an ataxia telangiectasia mutated-dependent manner. Cancer Res. 65(23), 10734-10741 (2005).
48. Freiberg RA, Hammond EM, Dorie MJ, Welford SM, Giaccia AJ: DNA damage during reoxygenation elicits a Chk2-dependent checkpoint response. Mol. Cell. Biol. 26(5), 1598-1609 (2006).
49. Hammond EM, Dorie MJ, Giaccia AJ: Inhibition of ATR leads to increased sensitivity to hypoxia/reoxygenation. Cancer Res. 64(18), 6556-6562 (2004).
50. Bristow R, Harrington L: Genomic instability and DNA repair In: The Basic Science of Oncology. Tannock I et al. (Eds). McGraw-Hill Ltd, New York, USA 77-99 (2005).
51. Fan R, Kumaravel TS, Jalali F, Marrano P, Squire JA, Bristow RG: Defective DNA strand break repair after DNA damage in prostate cancer cells: implications for genetic instability and prostate cancer progression. Cancer Res. 64(23), 8526-8533 (2004).
52. Choudhury A, Cuddihy A, Bristow RG: Radiation and new molecular agents part I targeting ATM-ATR checkpoints, DNA repair, and the proteasome. Semin. Radiat. Oncol. 16(1), 51-58 (2006).
53. Cuddihy AR, Bristow RG: The p53 protein family and radiation sensitivity: yes or no? Cancer Metastasis Rev. 23(3-4), 237-257 (2004).
54. Bindra RS, Schaffer PJ, Meng A et al.: Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells. Mol. Cell. Biol. 24(19), 8504-8518 (2004).
55. Bindra RS, Gibson SL, Meng A et al.: Hypoxia-induced down-regulation of BRCA1 expression by E2Fs. Cancer Res. 65(24), 11597-11604 (2005).
56. Hsing AW, Chokkalingam AP: Prostate cancer epidemiology. Front. Biosci. 11, 1388-1413 (2006).
57. Jain RK, Safabakhsh N, Sckell A et al.: Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. Proc. Natl. Acad. Sci. USA 95(18), 10820-10825 (1998).
58. Skov K, Adornat H, Bowden M et al.: Hypoxia in the androgen-dependent Shionogi model for prostate cancer at three stages. Radiat. Res. 162(5), 547-553 (2004).
59. Nahum AE, Movsas B, Horwitz EM, Stobbe CC, Chapman JD: Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: implications for the α/β ratio. Int. J. Radiat. Oncol. Biol. Phys. 57(2), 391-401 (2003).
60. Zolzer F, Streffer C: Increased radiosensitivity with chronic hypoxia in four human tumor cell lines. Int. J. Radiat. Oncol. Biol. Phys. 54(3), 910-920 (2002).
61. Koritzinsky M, Wouters BG, Amellern O, Pettersen EO: Cell cycle progression and radiation survival following prolonged hypoxia and re-oxygenation. Int. J. Radiat. Biol 77(3), 319-328 (2001).
62. Chan N, Bristow R, Milosevic M: Tumor hypoxia, DNA repair and prostate cancer progression: new targets and new therapies. Future Oncol. (2007) (In Press).
63. Sprong D, Janssen HL, Vens C, Bcgg AC: Resistance of hypoxic cells to ionizing radiation is influenced by homologous recombination status. Int. J. Radiat. Oncol. Biol. Phys. 64(2), 562-572 (2006).
64. Klein EA, Casey G, Silverman R: Generic susceptibility and oxidative stress in prostate cancer: integrated model with implications for prevention. Urology 68(6), 1145-1151 (2006).
65. Helleday T, Bryant HE, Schultz N: Poly(ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy. Cell Cycle 4(9), 1176-1178 (2005).
66. Madhusudan S, Middleton MR. The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancer. Cancer Treat. Rev. 31(8), 603-617 (2005).
67. Al Rashid ST, Dellaire G, Cuddihy A et al.: Evidence for the direct binding of phosphorylated p53 to sites of DNA breaks in vivo. Cancer Res. 65 (23), 10810-10821 (2005).